Biocartis confirms Idylla sales and patient value

Share this article

The first half year results of Biocartis confirm a successful expansion of Idylla™, Biocartis’ fully automated molecular diagnostics system. 114 instruments (up to June 30, 2015) have been sold to various larger and smaller hospitals and distributors in and outside Europe. Idylla™ allows for faster and more accurate treatment for patients.

The recent research study of Dr. Filip Janku, MD from MD Anderson (Houston, United States) on the analytical sensitivity and specificity of the IdyllaTM BRAF Mutation Test, confirms that the IdyllaTM BRAF Mutation Test is rapid and has high concordance with other routinely used but more complex BRAF mutation–detecting tests.